Emergent sells Bayview plant in Baltimore to Syngene

Emergent BioSolutions has sold its Bayview plant in Baltimore to Syngene for $36.5 million. Syngene is a contract development and manufacturing organization based in India and a subsidiary of Biocon. This acquisition marks Syngene’s first biologics production site in the United States. The Bayview facility will help Syngene expand its services and capabilities in the pharmaceutical market. Emergent BioSolutions has retained the rights to use manufacturing services and capacity at the Bayview site. This will support its future growth plans.